Beijing Sinotau International Pharmaceutical Technology Co., Ltd.
北京先通国际医药科技股份有限公司
Develops and commercializes diagnostic and therapeutic radiopharmaceuticals, with a 13-asset pipeline including a registrational-stage lutetium-177 radioligand for neuroendocrine neoplasms and fluorine-18 PET diagnostic imaging agents, in China.
Filings
The documents are on HKEXnews; we link to the originals.
| 2026-10-28 | PHIP | PHIP (1st submission) | HKEXnews |
Key figures
Latest period: 6M2026 (to 2026-06-30). As printed in the filing; the full track record is in the company overview.
- Revenue
- RMB61.3 million
- Gross margin
- 29.4%
- Net profit (loss)
- RMB-533.9 million
Matters the filing discloses
From the company’s latest filing; open a kind of matter to see how other companies disclosed it.
- Ten lease agreements not registered and filed
- Revenue contribution of the five largest customers accounted for up to 93.3%
- INPC as the sole supplier and manufacturer of lutetium-177 for XTR008
- Reliance on third-party in-licensing for multiple pipeline assets
- Outsourcing of R&D and production to CROs and CMOs
- 15-year marketing services agreement with Customer C and its termination
- Relatively low capacity utilisation of licensed production lines
- Cash burn rate and financial sustainability period
- Continuous increase in trade receivables and turnover days
- High inventory turnover days and impairment provisions
- Share redemption liabilities and changes in their fair value
- Expected substantial increase in net loss for 2026
- Gain on disposal of equity investments in Cerveau and Meilleur
- R&D stage of core products and uncertainty of successful development
- Sanctions risks from transactions with listed entities and Russia-produced ytterbium-176
Other applicants in the same industry
All of them: Biotech & Pharma
Produces and sells TCM decoction-ready products, traditional herbal preparations, wellness products and health management services to hospitals, medical trading companies, pharmacies, pharmaceutical companies and retail consumers across most Chinese provinces, Hong Kong, Taiwan and overseas markets. Ranked second in China with 0.4% market share in 2025.
Develops small-molecule drugs for autoimmune diseases and oncology, with one NMPA-approved drug (Mufemilast) and five clinical-stage candidates; markets drugs in China and holds patents in China, the US and other jurisdictions.
- Shandong Sinder Technology Co., Ltd.山东信得科技股份有限公司
Develops, produces and sells animal health products in the PRC, including veterinary vaccines, antibodies, Chinese veterinary medicines, drug formulations, and animal feed and additives for poultry, livestock, aquatic animals and pets. Ranked tenth in the PRC animal health market per CIC.
- ACROBIOSYSTEMS CO., LTD北京百普赛斯生物科技股份有限公司
Develops, produces and sells biological reagents—recombinant proteins, antibodies and analytical assay kits—plus technical services supporting biopharmaceutical R&D in China and globally. Per Frost & Sullivan, ranked third globally in recombinant proteins with a 2.7% revenue share in 2025.
- Zhejiang Jingxin Pharmaceutical Co., Ltd.浙江京新药业股份有限公司
Pharmaceutical group in China developing and selling drugs focused on CNS disorders and cardiovascular/cerebrovascular diseases, including generics, the innovative drug Dimdazenil, TCM, biologics, APIs, and medical equipment. 2025 revenue was RMB4,069.4 million with net profit of RMB771.7 million.
- SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.深圳信立泰药业股份有限公司
Develops, produces, and sells pharmaceuticals and medical devices focused on cardiovascular-kidney-metabolic diseases in China, including innovative drugs, generics, and biosimilars. Ranked second in in-hospital sales of cardiovascular drugs in China in 2025 with an 11.3% market share, per Frost & Sullivan.
- ProteLight Pharmaceuticals (Jiangsu) Co., Ltd.普莱医药（江苏）股份有限公司
Develops antimicrobial peptide therapeutics focusing on anti-infectives and metabolic diseases. Core product PL-5 (Peceleganan) is a topical spray treating secondary infections of burn wounds and diabetic foot infections. Operates in China.
- Hangzhou Bangshun Pharmaceutical Co., Ltd.杭州邦顺制药股份有限公司
Develops and commercializes oral small-molecule drugs for oncology and autoimmune diseases, with a pipeline including NMPA-approved bezacitinib, a JAK inhibitor for myelofibrosis, and one registrational candidate, operating in China.